These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21776440)

  • 1. Distance traveled and cross-state commuting to opioid treatment programs in the United States.
    Rosenblum A; Cleland CM; Fong C; Kayman DJ; Tempalski B; Parrino M
    J Environ Public Health; 2011; 2011():948789. PubMed ID: 21776440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of residence and race on burden of travel for care: cross sectional analysis of the 2001 US National Household Travel Survey.
    Probst JC; Laditka SB; Wang JY; Johnson AO
    BMC Health Serv Res; 2007 Mar; 7():40. PubMed ID: 17349050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disparities in access to opioid treatment programs and buprenorphine providers by race and ethnicity in the contiguous U.S.
    Amiri S; Panwala V; Amram O
    J Subst Use Addict Treat; 2024 Jan; 156():209193. PubMed ID: 37890620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spatial access to opioid treatment program and alcohol and cannabis outlets: analysis of missed doses of methadone during the first, second, and third 90 days of treatment.
    Amiri S; Lutz RB; McDonell MG; Roll JM; Amram O
    Am J Drug Alcohol Abuse; 2020; 46(1):78-87. PubMed ID: 31237791
    [No Abstract]   [Full Text] [Related]  

  • 5. Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane County Washington.
    Amiri S; Lutz R; Socías ME; McDonell MG; Roll JM; Amram O
    J Subst Abuse Treat; 2018 Oct; 93():26-30. PubMed ID: 30126538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of Medications for Opioid Use Disorder Among West Virginia Medicaid Enrollees Following Medicaid Coverage of Methadone.
    Harris SJ; Landis RK; Li W; Stein BD; Saloner B
    Subst Use Addctn J; 2024 Jan; 45(1):91-100. PubMed ID: 38258853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanding access to methadone treatment in Ohio through federally qualified health centers and a chain pharmacy: A geospatial modeling analysis.
    Iloglu S; Joudrey PJ; Wang EA; Thornhill TA; Gonsalves G
    Drug Alcohol Depend; 2021 Mar; 220():108534. PubMed ID: 33497963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accessibility of Opioid Treatment Programs Based on Conventional vs Perceived Travel Time Measures.
    Kim J; Lee J; Thornhill TA; Dennett J; Lu H; Howell B; Grau LE; Fiellin DA; Heimer R; Gonsalves G
    JAMA Netw Open; 2024 Feb; 7(2):e240209. PubMed ID: 38376839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Racial/Ethnic Differences in Prevalence Trends for Heroin use and Non-Medical use of Prescription Opioids Among Entrants to Opioid Treatment Programs, 2005-2016.
    Pouget ER; Fong C; Rosenblum A
    Subst Use Misuse; 2018 Jan; 53(2):290-300. PubMed ID: 28854060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Geographic variation in availability of opioid treatment programs across U.S. communities.
    Jehan S; Zahnd WE; Wooten NR; Seay KD
    J Addict Dis; 2024; 42(2):136-146. PubMed ID: 36645315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introduction of Medicare coverage in opioid treatment programs: Findings from the first three years.
    Abraham AJ; Harris SJ; Yarbrough CR
    J Subst Use Addict Treat; 2024 Mar; 158():209247. PubMed ID: 38072386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age differences in heroin and prescription opioid abuse among enrolees into opioid treatment programs.
    Cleland CM; Rosenblum A; Fong C; Maxwell C
    Subst Abuse Treat Prev Policy; 2011 Jun; 6():11. PubMed ID: 21635762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
    Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in prescription opioid analgesic availability: comparing minority and white pharmacies across Michigan.
    Green CR; Ndao-Brumblay SK; West B; Washington T
    J Pain; 2005 Oct; 6(10):689-99. PubMed ID: 16202962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescription opioid abuse among enrollees into methadone maintenance treatment.
    Rosenblum A; Parrino M; Schnoll SH; Fong C; Maxwell C; Cleland CM; Magura S; Haddox JD
    Drug Alcohol Depend; 2007 Sep; 90(1):64-71. PubMed ID: 17386981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Access to publicly funded methadone maintenance treatment in two western states.
    Deck D; Carlson MJ
    J Behav Health Serv Res; 2004; 31(2):164-77. PubMed ID: 15255224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Responses among substance abuse treatment providers to the opioid epidemic in the USA: Variations in buprenorphine and methadone treatment by geography, operational, and payment characteristics, 2007-16.
    Yang JC; Roman-Urrestarazu A; Brayne C
    PLoS One; 2020; 15(3):e0229787. PubMed ID: 32126120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states.
    Patrick SW; Buntin MB; Martin PR; Scott TA; Dupont W; Richards M; Cooper WO
    Subst Abus; 2019; 40(3):356-362. PubMed ID: 29949454
    [No Abstract]   [Full Text] [Related]  

  • 19. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.
    Levander XA; Pytell JD; Stoller KB; Korthuis PT; Chander G
    Subst Abus; 2022; 43(1):633-639. PubMed ID: 34666636
    [No Abstract]   [Full Text] [Related]  

  • 20. Methadone initiation in a bridge clinic for opioid withdrawal and opioid treatment program linkage: a case report applying the 72-hour rule.
    Laks J; Kehoe J; Farrell NM; Komaromy M; Kolodziej J; Walley AY; Taylor JL
    Addict Sci Clin Pract; 2021 Dec; 16(1):73. PubMed ID: 34961554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.